The U.S. Food and Drug Administration (FDA) approved the anticoagulant Xarelto in July 2011.
Anticoagulants are designed to reduce the risk of strokes and blood clots, but if blood levels are not managed properly, patients can experience life-threatening and irreversible internal bleeding after an injury. There is no antidote to reverse the blood thinning effects of Xarelto and some people have bled to death as a result. Manufacturers Bayer HealthCare Pharmaceuticals, Johnson & Johnson, and Janssen Pharmaceuticals failed to advise patients to monitor their blood levels, and now victims are seeking justice.
Xarelto was marketed as a more convenient alternative to Warfarin. However, unlike Warfarin, Xarelto has no antidote to reverse the effects of internal bleeding.
Serious Xarelto bleeding can occur in the gastrointestinal tract, brain or elsewhere in the body, and it can lead to substantial bleeding, extended hospitalization or death.
Patients may be at risk for Xarelto bleeding after taking as little as one dose. Victims are urged to contact a Xarelto lawyer to discuss filing a lawsuit and protecting their rights.
The Legal Examiner and our Affiliate Network strive to be the place you look to for news, context, and more, wherever your life intersects with the law.
Comments for this article are closed.